FDA approved Datroway (datroway) for EGFR-Mutated NSCLC and HR+ Breast CancerFDA approved new drug Datroway for two types of advanced cancer.

FDA From the archive Source published January 17, 2025 Summary added May 26, 2026 DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider Datroway for EGFR-mutated NSCLC after prior EGFR therapy and platinum chemo, and for HR+/HER2- breast cancer after endocrine and chemo.

The FDA has approved Datroway (datroway), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for two distinct indications. First, it is indicated for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication received accelerated approval based on objective response rate and duration of response, with continued approval contingent on verification of clinical benefit in a confirmatory trial. Second, Datroway is approved for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The approval provides a new treatment option for these patient populations, particularly those with limited alternatives after progression on standard therapies.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Datroway is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. The antibody component binds to Trop-2 on cancer cells, and after internalization, the topoisomerase inhibitor payload is released, leading to DNA damage and cell death.

Indication & Patient Population

Datroway is indicated for: - Adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. - Adult patients with unresectable or metastatic, HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

Dosing & Administration

The recommended dosage is 6 mg/kg (up to a maximum of 540 mg for patients ≥90 kg) administered as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity. Dose reductions are recommended for adverse reactions: first reduction to 4 mg/kg (max 360 mg), second to 3 mg/kg (max 270 mg), and permanently discontinue if unable to tolerate 3 mg/kg. Premedication includes preservative-free lubricant eye drops, steroid-containing mouthwash, antihistamine, antipyretic, and antiemetics. Reconstitute with Sterile Water for Injection and dilute with 5% Dextrose Injection; do not use Sodium Chloride Injection.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Not reported in label.

Place in Therapy

Datroway provides a targeted therapy option for patients with EGFR-mutated NSCLC after progression on EGFR-directed therapy and platinum-based chemotherapy, and for patients with HR-positive, HER2-negative breast cancer after endocrine-based therapy and chemotherapy. The NSCLC indication is under accelerated approval, requiring confirmatory trials to verify clinical benefit.

The FDA has approved a new drug called Datroway for two different types of advanced cancer. First, it is for adults with a specific kind of non-small cell lung cancer that has an EGFR mutation and has spread or cannot be removed by surgery. These patients must have already tried an EGFR-targeted therapy and platinum chemotherapy. Second, it is for adults with a type of breast cancer that is hormone receptor positive and HER2 negative (scores IHC 0, 1+, or 2+ with negative ISH). This breast cancer must be advanced or spread, and patients must have already received hormone therapy and chemotherapy.

Datroway works by targeting a protein called Trop-2 on cancer cells and delivering a drug that interferes with cancer cell growth. The approval for lung cancer is based on early results showing tumor shrinkage, but continued approval depends on a larger study confirming benefit. For breast cancer, the approval is based on a trial showing improved outcomes.

This approval offers a new option for patients who have run out of standard treatments. However, it is not a cure, and side effects are possible. Patients should talk to their doctor to see if Datroway is right for their specific situation.

What this means for you:

Datroway is a new option for certain advanced lung and breast cancers, but talk to your doctor about risks and benefits.

Study Details

Study typeFda approval

PublishedJan 2025

View Original Abstract ↓

1 INDICATIONS AND USAGE DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.2 ) 1.1 Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. 1.2 Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

FDA approved Datroway (datroway) for EGFR-Mutated NSCLC and HR+ Breast CancerFDA approved new drug Datroway for two types of advanced cancer.

Study Details

Combination of Local Treatment and Systemic Therapy Improves Outcomes in Patients with Hepatocellular Carcinoma

Combining local and systemic treatments improves survival in liver cancer

Clinical research that matters. Delivered to your inbox.

FDA approved Datroway (datroway) for EGFR-Mutated NSCLC and HR+ Breast CancerFDA approved new drug Datroway for two types of advanced cancer.

Study Details

Combination of Local Treatment and Systemic Therapy Improves Outcomes in Patients with Hepatocellular Carcinoma

Combining local and systemic treatments improves survival in liver cancer

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties